Neurosurgeons at the London Health Sciences Centre (LHSC) in Ontario now have a helping hand in the shape of a Renishaw robotic device to aid procedures.
The UK-based global company has introduced the first neuromate® stereotactic robot to Canada, with the technology designed to provide a reliable platform for diagnosis and therapy delivery.
Canada’s first procedure utilizing the device was a Stereo-electroencephalography (SEEG) case to measure electrical signals within the brain in order to identify the causes of epileptic seizures.
The robot guides surgical tools into position after the trajectory is pre-planned by the neurosurgeon, who still retains complete control over the process and patient.
“The robot totally changes how we approach insertion of SEEG electrodes,” said Dr. David Steven, neurosurgeon and co-director of the Epilepsy Program at the LHSC.
“It is already noticeably faster and more accurate than the previous system. In addition, it allows us to plan trajectories previously impossible with a standard frame, making surgery safer and more accurate.”
While this a first for Canada, neuromate® is already in use at healthcare centres around the world having been used in over 10,000 procedures.
LHSC has a history of innovation in the medical device industry and has been at the forefront of patient care, teaching and research excellence for more than 142 years.
“We are very excited at the opportunity of working together with the distinguished team at London Health Sciences Centre,” said Dr. Abed Hammoud, CEO of Renishaw Mayfield, Switzerland.
“Their advanced research and clinical practice will help us to continue pushing the neuromate to higher levels. Our team will support Dr Steven to continue providing best care for his patients.”